152 related articles for article (PubMed ID: 37589078)
1. Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV.
Sekiya R; Muramatsu T; Ichiki A; Chikasawa Y; Bingo M; Yotsumoto M; Hagiwara T; Amano K; Kinai E
J Infect Chemother; 2023 Feb; 29(2):171-178. PubMed ID: 37589078
[TBL] [Abstract][Full Text] [Related]
2. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
3. Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.
Hoffman RM; Brummel S; Ziemba L; Chinula L; McCarthy K; Fairlie L; Jean-Philippe P; Chakhtoura N; Johnston B; Krotje C; Nematadzira TG; Nakayiwa F; Ndyanabangi V; Hanley S; Theron G; Violari A; João E; Correa MD; Hofer CB; Navanukroh O; Aurpibul L; Nevrekar N; Zash R; Shapiro R; Stringer JSA; Currier JS; Sax P; Lockman S;
Clin Infect Dis; 2024 Jun; 78(6):1617-1628. PubMed ID: 38180851
[TBL] [Abstract][Full Text] [Related]
4. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
Plum PE; Maes N; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Paquot N; Fombellida K; Vaira D; Moutschen M; Darcis G
BMC Infect Dis; 2021 Sep; 21(1):910. PubMed ID: 34488664
[TBL] [Abstract][Full Text] [Related]
5. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Bosch B; Akpomiemie G; Chandiwana N; Sokhela S; Hill A; McCann K; Qavi A; Mirchandani M; Venter WDF
Clin Infect Dis; 2023 Apr; 76(8):1492-1495. PubMed ID: 36519389
[TBL] [Abstract][Full Text] [Related]
6. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
Gomez M; Seybold U; Roider J; Härter G; Bogner JR
Infection; 2019 Feb; 47(1):95-102. PubMed ID: 30269210
[TBL] [Abstract][Full Text] [Related]
7. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
[TBL] [Abstract][Full Text] [Related]
8. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
Kauppinen KJ; Aho I; Sutinen J
AIDS; 2022 Aug; 36(10):1337-1344. PubMed ID: 35727143
[TBL] [Abstract][Full Text] [Related]
9. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
Kanda N; Okamoto K; Okumura H; Mieno M; Sakashita K; Sasahara T; Hatakeyama S
HIV Med; 2021 Jul; 22(6):457-466. PubMed ID: 33720508
[TBL] [Abstract][Full Text] [Related]
10. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
[TBL] [Abstract][Full Text] [Related]
11. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes.
McCann K; Shah S; Hindley L; Hill A; Qavi A; Simmons B; Serenata C; Sokhela S; Venter WDF
AIDS; 2021 Aug; 35(10):1657-1665. PubMed ID: 33927086
[TBL] [Abstract][Full Text] [Related]
12. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
Asif S; Baxevanidi E; Hill A; Venter WDF; Fairlie L; Masenya M; Serenata C; Sokhela S; Chandiwana N
AIDS; 2021 Dec; 35(Suppl 2):S117-S125. PubMed ID: 34261099
[TBL] [Abstract][Full Text] [Related]
13. Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
Abe K; Obara T; Kamio S; Kondo A; Imamura J; Goto T; Ito T; Sato H; Takahashi N
AIDS Res Ther; 2021 Dec; 18(1):94. PubMed ID: 34876151
[TBL] [Abstract][Full Text] [Related]
14. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group.
Łomiak M; Stępnicki J; Mikuła T; Wiercińska-Drapało A
Int J STD AIDS; 2021 May; 32(6):570-577. PubMed ID: 33612018
[TBL] [Abstract][Full Text] [Related]
15. Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function.
Quesada-López T; Cereijo R; Blasco-Roset A; Mestres-Arenas A; Prieto P; Domingo JC; Villarroya F; Domingo P; Giralt M
Biochem Pharmacol; 2024 Feb; 220():116010. PubMed ID: 38154544
[TBL] [Abstract][Full Text] [Related]
16. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
[TBL] [Abstract][Full Text] [Related]
17. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization.
Brunet L; Mallon P; Fusco JS; Wohlfeiler MB; Prajapati G; Beyer A; Fusco GP
Clin Drug Investig; 2021 Nov; 41(11):955-965. PubMed ID: 34546533
[TBL] [Abstract][Full Text] [Related]
18. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
Hikasa S; Shimabukuro S; Hideta K; Higasa S; Sawada A; Tokugawa T; Tanaka K; Yanai M; Kimura T
J Infect Chemother; 2022 Mar; 28(3):396-400. PubMed ID: 34896027
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Venter WDF; Moorhouse M; Sokhela S; Fairlie L; Mashabane N; Masenya M; Serenata C; Akpomiemie G; Qavi A; Chandiwana N; Norris S; Chersich M; Clayden P; Abrams E; Arulappan N; Vos A; McCann K; Simmons B; Hill A
N Engl J Med; 2019 Aug; 381(9):803-815. PubMed ID: 31339677
[TBL] [Abstract][Full Text] [Related]
20. Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.
Schafer JJ; Zimmerman M; Walshe C; Cerankowski J; Shimada A; Keith SW
Obesity (Silver Spring); 2022 Jun; 30(6):1197-1204. PubMed ID: 35674696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
